Zusammenfassung
Eine Aknetherapie ist auch in der Schwangerschaft notwendig, um eine Verschlechterung, Narbenbildung, Superinfektion oder psychische Beeinträchtigung der Mutter zu verhindern. Sichere Produkte müssen ausgewählt werden. Tetrazykline, Doxyzyklin, Minozyklin oder Isotretinoin sind nicht einzusetzen. Topisches Benzoylperoxid und topische Azelainsäure sind sichere Therapiemöglichkeiten. Eine systemische Therapie kann bei ausgeprägt schwerer Akne nach den Leitlinien auch in der Schwangerschaft mit Glukokortikoiden ab dem 2. Trimenon in Zusammenarbeit mit dem Gynäkologen und/oder mit Erythromycin (Letzteres nicht in der Stillzeit) durchgeführt werden. Zink kann, falls nötig, oral gegeben werden, jedoch nicht länger als 3 Monate. Ergänzende kosmetologische Maßnahmen sind das manuelle Ausreinigen, Peeling-Maßnahmen wie ein mechanisches Peeling oder ein chemisches Peeling mit Glykol- oder Fruchtsäuren. Dagegen sollten Salicylsäure-, Trichloressigsäure- oder Phenol-Peels in der Schwangerschaft nicht eingesetzt werden. Camouflage kann die psychische Belastung seitens der Haut deutlich reduzieren.
Abstract
Acne should be treated during pregnancy to prevent worsening, scarring, secondary infection or psychological impairment of the mother. Safe products must be chosen. Systemic tetracycline, doxycycline, minocycline or isotretinoin can not be used. Topical benzoyl peroxide or topical azelaic acid are safe therapeutic options. According to the guidelines, systemic corticosteroids or systemic erythromycin (the latter not in lactation) can be employed beginning in the second trimester for severe flares of acne and should be started in cooperation with the patient’s gynecologist. Oral zinc is another option, but not for longer than 3 months. Accessory cosmetic measures may be useful, including mechanical peeling or chemical peeling with glycolic or alpha-hydroxy-acids. In contrast, salicylic acid, trichloracetic acid or phenol peels should not be performed in pregnancy. Camouflage makeup can clearly lower the psychological stress.
Literatur
Akhavan A, Bershad S (2004) Topical acne drugs: review of clinical properties, systemic exposure, and safety. Am J Clin Dermatol 4:473–492
American Academy of Pediatrics Committee on Drugs (1994) The transfer of drugs and other chemicals into human milk. Pediatrics 93:137–150
Autret E, Berjot M, Jonville-Berra AP et al (1997) Anophthalmia and agenesis of optic chiasm associated with adapalene gel in early pregnancy. Lancet 350:339
Barza M, Goldstein JA, Kane A et al (1982) Systemic absorption of clindamycin hydrochloride after topical application. J Am Acad Dermatol 7:208–214
Bayerl C, Degitz K, Meigel E, Kerscher M (2010) Adjuvant dermato-cosmetic acne therapy. JDDG 1:S89–S94
Becker LE, Bergstresser PR, Whiting DA et al (1981) Topical clindamycin therapy for acne vulgaris: a cooperative clinical study. Arch Dermatol 117:482–485
Borglund E, Hagermark O, Nord CE (1984) Impact of topical cindamycin and systemic tetracycline on the skin and colon microflora in patients with acne vulgaris. Scand J Infect Dis S43:76–81
Cooper WO, Griffin MR, Arbogast P et al (2002) Very early exposure to erythromycin and infantile hypertrophic pyloric stenosis. Arch Pediatr Adolesc Med 156:647–650
Cosmetic Ingredient Review Panel (2003) Safety assessment of Salicylic acid, Butyloctyl Salicylate, Calcium Salicylate, C12–15 Alkyl Salicylate, Caproyl Salicylic Acid, Hexyldodcyl Salicylate, Isocetyl Salicylate, Isodecyl Salicylate, Magnesium Salicylate, MEA-Salicylate, Athylhexyl Salicylate, Potassium Salicylate, Methyl Salicylate, Myristyl Salicylate, Potassium Salicylate, Methyl Salicylate, Myristyl Salicylate, Sodium Salicylate, and Tridecyl Salicylate. Int J Toxicol 22:1–108
Cunliffe WJ, Gollnick HPF, Orfanos CE (1993) Akne. Hippokrates, Stuttgart
Dréno B, Blouin E (2008) Acne, pregnant women and zinc salts: a literature review. Ann Dermatol Venerol 135:27–33
Duran B, Gursoy S, Cetin M et al (2004) The oral toxicity of resorcinol during pregnancy: a case report. J Toxicol Clin Toxicol 42:663–666
Fluhr JW, Gloor M, Merkel W et al (1998) Antibacterial and sebosuppressive efficacy of a combination of chloramphenicol and pale sulfonated shale oil. Multicentre, ranmdomized, vehicle controlled, double-blind study on 91 acne patients with acne papulopustulosa (Plewig and Kligman’s grade II–III). Arzneimittelforschung 48:188–196
Gallagher JC, Ismail MA, Aladjem S (1980) Reduced urinary levels with erythromycin therapy. Obstet Gynecol 56:318–382
Gollnick H (1993) Azelaic acid – pharmacology, toxicology and mechanism of action on keratinization in vitro and in vivo. J Dermatol Treat 4:S3–S7
Gollnick H, Cunliffe W, Berson D et al (2003) Global alliance to improve outcomes in acne. Management of acne: a report from a global alliance to improve outcomes in acne. J Am Acad Dermatol 49:S1–S37
Hale EK, Pomeranz MK (2002) Dermatologic agents during pregnancy and lactation: an update and clinical review. Int J Dermatol 41:197–203
Krautheim A, Gollnick H (2003) Transdermal penetration of topical drugs used in the treatment of acne. Clin Pharmacokinet 42:1287–304
Kretschmar R, Leuschner F (1975) Investigation on the toxicity of tretinoin administered systemically to animals. Acta Derm Venereol S74:25–28
Lammer EJ, Chen DT, Hoar RM et al (1985) Retinoid acid embryopathy. N Engl J Med 313:837–841
McCormack WM, George H, Donner A et al (1977) Hepatotoxicity of erythromycin estolate during pregnancy. Antimicrobe Agents Chemother 12:630–635
Milstone EB, McDonald AJ, Scholhamer CF Jr (1981) Pseudomembranous colitis after topical application of clindamycin. Arch Dermatol 117:154–155
Morsches B, Holzmann H (1982) Studies on the percutaneous absorption if benzoyl peroxide. Arzneimittel Forschung 32:298–300
Nacht S, Young D, Beasley JN et al (1981) Benzoyl peroxide percutaneous penetration and metabolic disposition. J Am Acad Dermatol 4:31–37
Nast A, BayerlC, Borelli C et al (2010) S2k-guideline for therapy of acne. JDDG 8 S2:1–59
Nau H (1993) Embryotoxicity and teratogenicity of topical retinoic acid. Skin Pharmakol 6:35–44
Parry MF, Rha CK (1986) Pseudomembranous colitis caused by topical clindamycin phosphate. Arch Dermatol 122:583–584
Rothman KF, Pochi PE (1988) Use of oral and topical agents for acne in pregnancy. J Am Acad Dermatol 19:431–442
Sasseville D (1996) Dermatological therapy during pregnancy and lactation. In: Harahap, M, Wallach RC (Hrsg) Skin changes and disease in pregnancy. Marcel Dekker, New York, S 249–319
(o A) (2011) Skin-lightening cosmetics: frequent, potentially severe adverse effects. Prescrire Int 20:209–213
Stéphan F, Revuz J (2004) Zinc salts in dermatology. Ann Dermatol Venerol 13:455–460
Tauber U, Weiss C, Matthes H (1992) Percutaneous absorption of azelaic acid in humans. Exp Dermatol 1:176–179
Van Hoogdalem EJ (1998) Transdermal absorption of topical anti-acne agents in man; review of clinical pharmacokinetic data. J Eur Acad Dermatol Venereol 11 S1:13–19
Weinstein AJ, Gibbs RE, Gallagher M (1976) Placental transfer of clindamycin and gentamicin in term pregnancy. Am J Obstet Gynecol 124:688–691
Worret WI, Fluhr JW (2006) Acne therapy with topical benzoyl peroxide, antibiotics and azelaic acid. JDDG 4:293–300
Zbinden G (1975) Aspects of teratology of vitamin A acid (beta-all-trans- retinoic acid). Acta Derm Venerol S74:36–40
Interessenkonflikt
Die korrespondierende Autorin weist auf folgende Beziehungen hin: Unterstützung zu Symposien, Vorträgen und Aufwandsentschädigungen für Studien und Advisory-Board-Tätigkeiten von Firmen, die Aknepräparate, Peelingsubstanzen und Camouflage-Produkte herstellen.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bayerl, C. Aknetherapie in der Schwangerschaft. Hautarzt 64, 269–273 (2013). https://doi.org/10.1007/s00105-012-2456-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00105-012-2456-2